The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease

被引：16

作者：

Makitalo, Signar ^{[1
]}

Mellgren, Asa ^{[2
,3
]}

Borgh, Ellen ^{[4
]}

Kilander, Lena ^{[5
]}

Skillback, Tobias ^{[6
]}

Zetterberg, Henrik ^{[6
,7
]}

Gisslen, Magnus ^{[3
]}

机构：

[1] Gavle Cent Hosp, Dept Infect Dis, S-80187 Gavle, Sweden

[2] South Alvsborg Hosp, Clin Infect Dis, Boras, Sweden

[3] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Infect Dis, Gothenburg, Sweden

[4] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Resp Med, Gothenburg, Sweden

[5] Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden

[6] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden

[7] UCL Inst Neurol, London, England

来源：

AIDS RESEARCH AND THERAPY | 2015年 / 12卷

基金：

瑞典研究理事会;

关键词：

Alzheimer's disease; HIV; CSF biomarkers; NEUROFILAMENT PROTEIN NFL; CENTRAL-NERVOUS-SYSTEM; ANTIRETROVIRAL THERAPY; LIFE EXPECTANCY; TAU-PROTEIN; DEMENTIA; CSF; INDIVIDUALS; DIAGNOSIS; MARKER;

D O I：

10.1186/s12981-015-0063-x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

It is a challenge to differentiate between HIV-associated neurocognitive disorders (HAND) and other types of neurocognitive disease in the ageing HIV-infected population. Here we describe a 63 year old HIV-infected woman who had a history, neuropsychological test result, and PET examination consistent with characteristic Alzheimer's disease (AD). The cerebrospinal fluid (CSF) biomarker profile was analogous to the profile typically found in AD in HIV-negative patients with increased t-tau and p-tau, a decreased level of A beta 42 and normal levels of CSF neurofilament light protein and sAPP alpha and sAPP beta, distinctly different from findings in HIV-associated dementia (HAD). Assessment of CSF biomarkers may be a valuable tool for clinicians to distinguish between HAD and AD.

引用

页数：5

共 50 条

[21] Idiopathic Normal Pressure Hydrocephalus has a Different Cerebrospinal Fluid Biomarker Profile from Alzheimer's Disease [J].

Jingami, Naoto ;

Asada-Utsugi, Megumi ;

Uemura, Kengo ;

Noto, Rio ;

Takahashi, Makio ;

Ozaki, Akihiko ;

Kihara, Takeshi ;

Kageyama, Takashi ;

Takahashi, Ryosuke ;

Shimohama, Shun ;

Kinoshita, Ayae .

JOURNAL OF ALZHEIMERS DISEASE, 2015, 45 (01) :109-115

[22] Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting [J].

Malnar, Martina ;

Kosicek, Marko ;

Bene, Raphael ;

Tarnik, Iva Petek ;

Pavelin, Sanda ;

Babic, Ivana ;

Brajenovic-Milic, Bojana ;

Hecimovic, Hrvoje ;

Titlic, Marina ;

Trkanjec, Zlatko ;

Demarin, Vida ;

Hecimovic, Silva .

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2012, 72 (03) :264-271

[23] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease [J].

Andreasen, N ;

Blennow, K .

PEPTIDES, 2002, 23 (07) :1205-1214

[24] Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals [J].

Letendre, Scott L. ;

Zheng, Jialin C. ;

Kaul, Marcus ;

Yiannoutsos, Constantin T. ;

Ellis, Ronald J. ;

Taylor, Michael J. ;

Marquie-Beck, Jennifer ;

Navia, Bradford .

JOURNAL OF NEUROVIROLOGY, 2011, 17 (01) :63-69

[25] Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study [J].

Lleo, Alberto ;

Alcolea, Daniel ;

Martinez-Lage, Pablo ;

Scheltens, Philip ;

Parnetti, Lucilla ;

Poirier, Judes ;

Simonsen, Anja H. ;

Verbeek, Marcel M. ;

Rosa-Neto, Pedro ;

Slot, Rosalinde E. R. ;

Tainta, Mikel ;

Izaguirre, Andrea ;

Reijs, Babette L. R. ;

Farotti, Lucia ;

Tsolaki, Magda ;

Vandenbergue, Rik ;

Freund-Levi, Yvonne ;

Verhey, Frans R. J. ;

Clarimon, Jordi ;

Fortea, Juan ;

Frolich, Lutz ;

Santana, Isabel ;

Luis Molinuevo, Jose ;

Lehmann, Sylvain ;

Visser, Pieter J. ;

Teunissen, Charlotte E. ;

Zetterberg, Henrik ;

Blennow, Kaj .

ALZHEIMERS & DEMENTIA, 2019, 15 (06) :742-753

[26] Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects [J].

Shaw, Leslie M. ;

Vanderstichele, Hugo ;

Knapik-Czajka, Malgorzata ;

Clark, Christopher M. ;

Aisen, Paul S. ;

Petersen, Ronald C. ;

Blennow, Kaj ;

Soares, Holly ;

Simon, Adam ;

Lewczuk, Piotr ;

Dean, Robert ;

Siemers, Eric ;

Potter, William ;

Lee, Virginia M. -Y. ;

Trojanowski, John Q. .

ANNALS OF NEUROLOGY, 2009, 65 (04) :403-413

[27] Aβ42 as a Biomarker of Alzheimer's Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid? [J].

Boschi, Silvia ;

Roveta, Fausto ;

Grassini, Alberto ;

Marcinno, Andrea ;

Cermelli, Aurora ;

Ferrandes, Fabio ;

Rainero, Innocenzo ;

Rubino, Elisa .

BRAIN SCIENCES, 2022, 12 (12)

[28] Cerebrospinal fluid biomarker for Parkinson's disease: An overview [J].

Maass, Fabian ;

Schulz, Isabel ;

Lingor, Paul ;

Mollenhauer, Brit ;

Baehr, Mathias .

MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 :60-66

[29] Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease [J].

Guo, Liang-Hao ;

Alexopoulos, Panagiotis ;

Perneczky, Robert .

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2013, 263 (07) :553-560

[30] Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia [J].

Kidemet-Piskac, Spomenka ;

Leko, Mirjana Babic ;

Blazekovic, Antonela ;

Horvat, Lea Langer ;

Klepac, Natasa ;

Sonicki, Zdenko ;

Kolenc, Danijela ;

Hof, Patrick R. ;

Boban, Marina ;

Mimica, Ninoslav ;

Borovecki, Fran ;

Simic, Goran .

CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (08) :734-740

← 1 2 3 4 5 →